false 0001380106 0001380106 2026-11-16 2026-11-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 16, 2026

 

 

Rapid Micro Biosystems, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware 001-40592 20-8121647
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)

 

25 Hartwell Avenue,
Lexington, MA
  02421
(Address of Principal Executive Offices)   (Zip Code)
     

 

Registrant’s Telephone Number, Including Area Code: (978) 349-3200

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading
symbol(s)
  Name of each exchange
on which registered
Class A common stock, $0.01 par value per share   RPID   The Nasdaq Capital Market

  

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 1.01. Entry into a Material Definitive Agreement.

 

On November 16, 2026, Rapid Micro Biosystems, Inc., a Delaware corporation (the “Company”), Merck KGaA, Darmstadt, Germany, a German corporation with general partners (“Parent”), and EMD Holdings NewCo II, Inc, a Delaware corporation and a wholly owned subsidiary of Parent (“Purchaser”), entered into an Agreement and Plan of Merger (the “Merger Agreement”). Pursuant to the Merger Agreement, and upon the terms and subject to the conditions therein, Purchaser will commence a cash tender offer (the “Offer”) to acquire all of the issued and outstanding shares of Class A common stock, $0.01 par value per share, and Class B common stock, $0.01 par value per share (collectively “Company Common Stock”), at a price per share of $0.75 (the “Offer Price”), without interest and subject to any withholding of taxes required by applicable law. The Offer will initially expire at one minute after 11:59 p.m. Eastern Time on the date that is 10 business days following the commencement of the Offer, subject to extension under certain circumstances.

 

Purchaser’s obligation to accept for payment shares of Company Common Stock validly tendered pursuant to the Offer is subject to the satisfaction or waiver, to the extent permitted under applicable legal requirements, of certain conditions set forth in the Merger Agreement, including that (i) there shall have been validly tendered (and not validly withdrawn) shares of Class A common stock (“Class A Common Shares”) that, considered together with all other Class A Common Shares (if any) owned by Parent and its affiliates, but excluding Class A Common Shares that have not yet been “received” (as such term is defined by Section 251(h)(6) of the DGCL), would represent one more Class A Common Share than 50% of the total number of (1) Class A Common Shares issued and outstanding as of immediately following the “consummation” of the Offer (as such term is defined in Section 251(h)(6) of the DGCL) plus (2) any Pre-Funded Warrant Shares (as defined below) (the “Minimum Condition”); (ii) the representations and warranties of the Company contained in the Merger Agreement shall be accurate, subject to customary materiality thresholds and exceptions; (iii) the Company shall have complied with and performed in all material respects each of the covenants and other obligations contained in the Merger Agreement; (iv) since the execution and delivery of the Merger Agreement, there shall not have occurred any Material Adverse Effect (as defined in the Merger Agreement) that is continuing as of the expiration of the Offer; (v) there shall not have been issued by any governmental body of competent jurisdiction and remain in effect any order, nor shall any law have been promulgated, enacted, issued or deemed applicable to the Offer or the Merger by any governmental body that remains in effect, in each case that prohibits or makes illegal the consummation of the Offer or the Merger; and (vi) other customary conditions set forth in Annex I of the Merger Agreement.

 

Following the consummation of the Offer, upon the terms and subject to the conditions set forth in the Merger Agreement, and in accordance with the DGCL, Purchaser will merge with and into the Company, with the Company continuing as the surviving corporation and as a wholly owned subsidiary of Parent (the “Merger”). The Merger will be governed by Section 251(h) of the DGCL, with no stockholder vote required in order to consummate the Merger.

 

Pursuant to the Merger Agreement, at the effective time of the Merger (the “Effective Time”), by virtue of the Merger and without any action on the part of any stockholder of the Company, each share of Company Common Stock (other than shares of Company Common Stock (a) held by the Company (or held in the Company’s treasury), Parent, Purchaser or any of their direct or indirect wholly owned subsidiaries, (b) irrevocably accepted for purchase in the Offer, or (c) with respect to which the holders thereof have properly exercised and perfected demands for appraisal in accordance with Section 262 of the DGCL) will be converted into the right to receive the Offer Price, in cash, without interest and subject to any withholding of taxes required by applicable law (the “Merger Consideration”).

 

In addition, at the Effective Time, by virtue of the Merger and without any action on the part of any holder thereof:

 

·

each option to purchase shares of Company Common Stock (each, a “Company Option”) (or portion thereof) that is vested and outstanding as of immediately prior to the Effective Time (taking into account any acceleration of vesting that occurs as of immediately prior to the Effective Time pursuant to the terms of such Company Option as in effect on the date of the Merger Agreement) will automatically be cancelled and converted into the right to receive an amount in cash, without interest and less any applicable tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Company Common Stock subject to such vested Company Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the per share exercise price of such Company Option; 

 

 

 

 

·each Company Option that is unvested and outstanding as of immediately prior to the Effective Time (taking into account any acceleration of vesting that occurs as of immediately prior to the Effective Time pursuant to the terms of such Company Option as in effect on the date of the Merger Agreement) will be converted into a fixed cash-based award (a “Parent Cash-Based Option Award”) representing the right to receive an amount in cash, without interest and less any applicable tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Company Common Stock subject to such unvested Company Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the per share exercise price of such Company Option. Each Parent Cash-Based Option Award will continue to vest on the same vesting schedule, and will otherwise remain subject to the same terms and conditions (subject to certain exceptions), as applied to the corresponding Company Option (or portion thereof) immediately prior to the Effective Time;

 

·each Company Option, whether vested or unvested, with a per share exercise price equal to or greater than the Merger Consideration will be cancelled for no consideration;

 

·each restricted stock unit award in respect of shares of Company Common Stock that is subject only to time-based vesting (each, a “Company RSU”) that is vested and outstanding as of immediately prior to the Effective Time (taking into account any acceleration of vesting pursuant to the terms of such Company RSU as in effect on the date of the Merger Agreement) will be cancelled and converted into the right to receive an amount in cash, without interest and less any applicable tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Company Common Stock subject to such vested Company RSU awards immediately prior to the Effective Time multiplied by (ii) the Merger Consideration;

 

·each Company RSU award (or portion thereof) that is unvested and outstanding immediately prior to the Effective Time (taking into account any acceleration of vesting pursuant to the terms of such Company RSU as in effect on the date of the Merger Agreement) will be converted into a fixed time-based cash-based award (a “Parent Cash-Based RSU Award”) representing the right to receive an amount in cash, less any applicable tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Company Common Stock subject to such unvested Company RSU award immediately prior to the Effective Time multiplied by (ii) the Merger Consideration. Each Parent Cash-Based RSU Award will continue to vest on the same vesting schedule, and will otherwise remain subject to the same terms and conditions (subject to certain exceptions), as applied to the corresponding Company RSU immediately prior to the Effective Time;

 

·each restricted stock unit award in respect of shares of Company Common Stock that is subject to both time-based and performance-based vesting (each, a “Company PSU”) that is vested and outstanding as of immediately prior to the Effective Time (taking into account any acceleration of vesting pursuant to the terms of such Company PSU as in effect on the date of the Merger Agreement) will be cancelled and converted into the right to receive an amount in cash, without interest and less any applicable tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the number of shares of Company Common Stock subject to such vested Company PSU award immediately prior to the Effective Time multiplied by (ii) the Merger Consideration; provided that, for purposes of determining the number of Company PSUs outstanding immediately prior to the Effective Time, with respect to any portion of the Company PSU award with a performance period that has not been completed as of such time, any applicable performance-based conditions shall be deemed to have been achieved at target performance; and

 

·

each Company PSU award (or portion thereof) that is unvested and outstanding as of immediately prior to the Effective Time (taking into account any acceleration of vesting pursuant to the terms of such Company PSU as in effect on the date of the Merger Agreement) will be converted into a fixed performance-based cash-based award (a “Parent Cash-Based PSU Award”) representing the right to receive an amount in cash, less any applicable tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the number of shares of Company Common Stock subject to such unvested Company PSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration; provided that, for purposes of determining the number of Company PSUs outstanding immediately prior to the Effective Time, with respect to any portion of the Company PSU award with a performance period that has not been completed as of such time, any applicable performance-based conditions shall be deemed to have been achieved at target performance. Each Parent Cash-Based PSU Award will continue to vest on the same performance-based vesting schedule, and will otherwise remain subject to the same terms and conditions (subject to certain exceptions), as applied to the corresponding Company PSU immediately prior to the Effective Time.

 

 

 

 

Pursuant to the Merger Agreement, with respect to the Company’s 2021 Employee Share Purchase Plan (the “ESPP”), the Company will take all actions necessary so that (i) no new participants may join the ESPP and current participants may not increase their payroll deductions or purchase elections, (ii) no new offering period will begin under the ESPP after the date of the Merger Agreement, and (iii) if the purchase date for the current offering period would otherwise fall on or after the Effective Time, that offering period will end on a new final purchase date no later than five business days before the Effective Time. The ESPP will terminate effective immediately prior to, and subject to, the consummation of the Merger.

 

Further, at the Effective Time (except as otherwise noted below):

 

·each warrant to purchase Class A Common Shares issued by the Company on each of May 20, 2026 and May 29, 2026, with an initial exercise price of $1.955 per Class A Common Share (the “Series A Common Stock Warrants”) that is issued and outstanding shall, in accordance with its terms, become exercisable by the holder thereof solely for an amount in cash equal to (i) the Merger Consideration such holder would have been entitled to receive at the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares then issuable upon exercise in full of such Series A Common Stock Warrant, without regard to any limitations on exercise contained therein, less (ii) the exercise price per share of such Series A Common Stock Warrant, in each case without interest, and less any applicable Tax withholding;

 

·each warrant to purchase Class A Common Shares issued by the Company on each of May 20, 2026 and May 29, 2026, with an initial exercise price of $2.34 per Class A Common Share (the “Series B Common Stock Warrants”) that is issued and outstanding shall, unless otherwise elected by the holder thereof in accordance with its terms, and in accordance with the Series B Warrant Cancellation Agreements (as defined in the Merger Agreement), be cancelled and purchased by Parent, such that Parent will pay to each holder of a Series B Common Stock Warrant an amount in cash equal to the Black Scholes Value (as defined in the Series B Common Stock Warrants) of the remaining unexercised portion of such Series B Common Stock Warrant;

 

·each warrant to purchase Class A Common Shares issued on August 8, 2025, with an initial exercise price of $3.35 per Class A Common Share (the “2025 Warrants”) that is issued and outstanding shall, in accordance with the 2025 Warrant Cancellation Agreements (as defined in the Merger Agreement), as applicable, be terminated and cancelled without any consideration;

 

·each pre-funded warrant to purchase Class A Common Shares issued by the Company on May 20, 2026, with an initial exercise price of $0.01 per Class A Common Share (the “Pre-Funded Warrants”) that is issued and outstanding shall, in accordance with its terms, be deemed to be exercised in full by the holder thereof in a “cashless exercise” pursuant to the terms thereof effective immediately prior to and contingent upon the occurrence of the Effective Time, it being understood that any shares issued upon such deemed “cashless exercise” (such shares, the “Pre-Funded Warrant Shares”) shall be treated pursuant to Section ‎2.5 of the Merger Agreement and no separate consideration shall be payable to the holder of any such Pre-Funded Warrant;

 

·each warrant to purchase shares of Company preferred stock designated as series A1, with an initial exercise price of $0.01 per share, which were converted into warrants to purchase Class A Common Shares with an exercise price of $0.05 per share on July 14, 2021 (the “Converted Series A-1 Preferred Stock Warrants”) and each warrant to purchase shares of Company preferred stock designated as series B1, with an initial exercise price of $0.01 per share, which were converted into warrants to purchase Class A Common Shares with an exercise price of $0.05 per share on July 14, 2021 (the “Converted Series B-1 Preferred Stock Warrants”) shall, at the time of the acceptance of the Company Common Stock in the Offer, be terminated in exchange for an amount in cash equal to (i) the Merger Consideration such holder would have been entitled to receive at the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares then issuable upon exercise in full of such Converted Series A-1 Preferred Stock Warrant and Converted Series B-1 Preferred Stock Warrant, as applicable, without regard to any limitations on exercise contained therein, less (ii) the exercise price per share of such Converted Series A-1 Preferred Stock Warrant and Converted Series B-1 Preferred Stock Warrant, as applicable, in each case without interest, and less any applicable tax withholding;

 

 

 

 

·each warrant to purchase shares of Company preferred stock designated as series C1, with an initial exercise price of $1.15 per share, which were converted into warrants to purchase Class A Common Shares with an exercise price of $5.75 per share on July 14, 2021 (the “Converted Series C-1 Preferred Stock Warrants”) shall be terminated in exchange for the right of the holder to receive an amount in cash equal to (i) the Merger Consideration such holder would have been entitled to receive at the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares then issuable upon exercise in full of such Converted Series C-1 Preferred Stock Warrant, without regard to any limitations on exercise contained therein, less (ii) the exercise price per share of such Converted Series C-1 Preferred Stock Warrant, in each case without interest, and less any applicable tax withholding; and

 

·each warrant to purchase Class A Common Shares issued on April 12, 2018, with an initial exercise price of $1.00 per Class A Common Share (the “2018 Warrants”) shall be automatically terminated and cancelled pursuant to the terms thereof without any consideration.

 

The Merger Agreement includes customary representations, warranties and covenants of the Company, Parent and Purchaser for a transaction of this nature, including covenants regarding the operation of the Company’s business prior to the Effective Time.

 

The Company has agreed to customary “no-shop” restrictions on its ability to solicit alternative acquisition proposals from third parties and engage in discussions or negotiations with third parties regarding acquisition proposals. Notwithstanding these restrictions, the Company may under certain circumstances provide information to and participate in discussions or negotiations with third parties with respect to an unsolicited bona fide written Acquisition Proposal (as such term is defined in the Merger Agreement) that the board of directors of the Company (the “Company Board”) has determined constitutes or would reasonably be expected to lead to a Superior Proposal (as such term is defined in the Merger Agreement) and that the failure to take such action would be inconsistent with the fiduciary duties of the Company Board under applicable law.

 

The Merger Agreement also provides that, in connection with the termination of the Merger Agreement under certain specified circumstances, including termination by the Company to accept and enter into an agreement with respect to a Superior Proposal or a Company Adverse Recommendation Change (as defined in the Merger Agreement), the Company will be required to pay Parent a termination fee in the amount of $1,573,000.

 

The Company Board has unanimously (i) determined that the Merger Agreement and the transactions, including the Offer and the Merger, are fair to and in the best interest of the Company and its stockholders, (ii) declared it advisable for the Company to enter into the Merger Agreement, (iii) approved the execution and delivery by the Company of the Merger Agreement, the performance by the Company of its obligations under the Merger Agreement and the consummation of the transactions, including the Offer and the Merger, (iv) resolved that the Merger shall be effected under Section 251(h) of the DGCL and (v) resolved to recommend that the stockholders of the Company accept the Offer and tender their shares to Purchaser pursuant to the Offer.

 

Tender and Support Agreements

 

Concurrently with the execution and delivery of the Merger Agreement, certain stockholders of the Company, including all of the members of the Company Board and certain executive officers of the Company, who collectively beneficially own approximately 19.58% of the outstanding shares of Company Common Stock entered into Tender and Support Agreements (the “Support Agreements”) with Parent and Purchaser. The Support Agreements provide, among other things, that each applicable stockholder will tender all of the shares of Company Common Stock held by such stockholder to Purchaser in the Offer. The Support Agreements will terminate upon certain events, including upon any valid termination of the Merger Agreement.

 

The foregoing description of the Merger Agreement is not complete and is qualified in its entirety by reference to the full text of the Merger Agreement, which is attached as Exhibit 2.1 to this report and incorporated herein by reference.

 

 

 

 

The Merger Agreement and the foregoing description thereof have been included to provide investors and stockholders with information regarding the terms of the Merger Agreement. They are not intended to provide any other factual information about the Company or Parent. The representations, warranties and covenants contained in the Merger Agreement were made only as of specified dates for the purposes of such agreement, were solely for the benefit of the parties to such agreement and may be subject to qualifications and limitations agreed upon by such parties. In particular, in reviewing the representations, warranties and covenants contained in the Merger Agreement and discussed in the foregoing description, it is important to bear in mind that such representations, warranties and covenants were negotiated with the principal purpose of allocating risk between the parties, rather than establishing matters as facts. Such representations, warranties and covenants may also be subject to a contractual standard of materiality different from those generally applicable to stockholders and reports and documents filed with the U.S. Securities and Exchange Commission (the “SEC”), and are also qualified in important part by a confidential disclosure schedule delivered by the Company to Parent in connection with the Merger Agreement. Investors and stockholders should not rely on such representations, warranties and covenants as characterizations of the actual state of facts or circumstances described therein. Information concerning the subject matter of such representations, warranties and covenants may change after the date of the Merger Agreement, which subsequent information may or may not be fully reflected in the parties’ public disclosures.

 

Item 8.01. Other Information.

 

On November 16, 2026, the Company issued a press release announcing the execution of the Merger Agreement. A copy of this press release is filed herewith as Exhibit 99.1.

 

Additional Information about the Proposed Transaction and Where to Find It

 

The tender offer referred to in this report has not yet commenced. This report is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell shares, nor is it a substitute for the tender offer materials that Parent and its acquisition subsidiary will file with the SEC upon commencement of the tender offer. At the time the tender offer is commenced, Parent and its acquisition subsidiary will cause to be filed a tender offer statement on Schedule TO with the SEC, and the Company will file a solicitation/recommendation statement on Schedule 14D-9 with respect to the tender offer. THE TENDER OFFER STATEMENT (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND OTHER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT WILL CONTAIN IMPORTANT INFORMATION THAT SHOULD BE READ CAREFULLY AND CONSIDERED BY THE COMPANY’S STOCKHOLDERS BEFORE ANY DECISION IS MADE WITH RESPECT TO THE TENDER OFFER. Both the tender offer statement and the solicitation/recommendation statement will be mailed to the Company’s stockholders free of charge. A free copy of the tender offer statement and the solicitation/recommendation statement will also be made available to all stockholders of the Company by accessing www.rapidmicrobio.com or by contacting the Company’s Investor Relations contact at investors@rapidmicrobio.com. In addition, the tender offer statement and the solicitation/recommendation statement (and all other documents filed with the SEC) will be available at no charge on the SEC’s website: www.sec.gov, upon filing with the SEC.

 

THE COMPANY’S STOCKHOLDERS ARE ADVISED TO READ THE SCHEDULE TO AND THE SCHEDULE 14D-9, AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BEFORE THEY MAKE ANY DECISION WITH RESPECT TO THE TENDER OFFER, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES THERETO.

 

 

 

 

Cautionary Statement Regarding Forward-Looking Statements

 

This report contains forward-looking statements regarding, among other things, the proposed acquisition of the Company by Parent, the expected timetable for completing the transaction, the Company’s future operating and financial performance, its business strategy and growth outlook, including with respect to its Growth Direct platform and systems, and its ability to develop and commercialize new and enhanced products and solutions. Words such as “anticipates,” “continue,” “could,” “may,” “forecasts,” “expects,” “intends,” “plans,” “potentially,” “believes,” “seeks,” “estimates,” “predict,” “target,” and variations of such words and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict; therefore, actual results may differ materially from those expressed or forecasted in any such statements. Such forward-looking statements are based on current expectations, estimates and projections about the Company’s industry and business, management's beliefs, and certain assumptions made by the Company’s management. Actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: (i) risks associated with the timing of the closing of the proposed transaction, including the risks that a condition to closing would not be satisfied within the expected timeframe or at all or that the closing of the proposed transaction will not occur; (ii) uncertainties as to how many of the Company’s stockholders will tender their shares in the offer; (iii) the possibility that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction; (iv) the possibility that competing offers will be made; (v) the occurrence of any event, change or other circumstance that could give rise to the termination of the transaction; (vi) the outcome of any legal proceedings that may be instituted against the parties and others related to the merger agreement; (vii) unanticipated difficulties or expenditures relating to the proposed transaction, the response of business partners and competitors to the announcement of the proposed transaction, and/or potential difficulties in employee retention as a result of the announcement and pendency of the proposed transaction; (viii) the Company’s ability to achieve positive cash flow and otherwise achieve its business objectives; (ix) the Company’s ability to meet its publicly announced guidance and other expectations regarding its business and operations; (x) the Company’s ability to fulfill customer orders on anticipated timelines or at all; (xi) the impact of the Company’s existing and any future indebtedness on its ability to operate its business and its ability to access additional funding under its debt facility; (xii) the effectiveness of the Company’s sales force and sales processes and its ability to maintain and expand its customer base; (xiii) the Company’s ability to anticipate market needs and successfully develop and launch new and enhanced products and solutions; (xiv) the Company’s ability to hire and retain qualified employees; (xv) risks related to the Company’s manufacturing, supply chain, regulatory and intellectual property matters; (xvi) the impact of inflation, interest rates, tariffs, trade policy and other macroeconomic conditions on the Company’s business and operations; and (xvii) those risks detailed in the Company’s most recent Annual Report on Form 10-K and subsequent reports filed with the SEC, as well as other documents that may be filed by the Company from time to time with the SEC. The Company cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. The forward-looking statements made in this report relate only to events as of the date on which the statements are made. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events.

 

 

 

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

     

Exhibit

No.

  Description
   
2.1*   Agreement and Plan of Merger, dated as of November 16, 2026 by and among Merck KGaA, Darmstadt, Germany, EMD Holdings NewCo II, Inc and Rapid Micro Biosystems, Inc.
   
99.1   Press Release issued by Rapid Micro Biosystems, Inc. on November 16, 2026
   
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

* Schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish supplemental copies of any of the omitted schedules upon request by the SEC; provided, however, that the Company may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934 for any schedules so furnished.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  RAPID MICRO BIOSYSTEMS, INC.
     
Date: November 16, 2026 By:

/s/ Sean Wirtjes

  Name: Sean Wirtjes
  Title: Chief Financial Officer